Compare Stocks: ANTX, TBPH, HELP, and ACHV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.58 -3.3%	$7.00	$2.62 ▼ $8.64	$780.00M	2.25	1.33 million shs	1.58 million shs
ANTX Anthem	$5.70 -4.7%	$5.33	$1.00 ▼ $7.19	$214.98M	-0.99	670,884 shs	106,548 shs
HELP Cybin	$13.45 +8.5%	$9.56	$3.76 ▼ $14.35	$1.02B	0.63	1.20 million shs	1.49 million shs
TBPH Theravance Biopharma	$17.06 0.0%	$16.95	$13.08 ▼ $21.03	$885.50M	0.25	562,162 shs	164,156 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-7.66%	-4.97%	+17.89%	+36.35%	+167.58%
ANTX Anthem	+1.53%	+9.12%	+0.84%	+42.38%	+398.33%
HELP Cybin	+1.39%	+6.81%	+6.72%	+220.16%	+1,238,999,900.00%
TBPH Theravance Biopharma	-0.12%	+0.18%	+0.77%	+4.22%	+22.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.58 -3.3%	$7.00	$2.62 ▼ $8.64	$780.00M	2.25	1.33 million shs	1.58 million shs
ANTX Anthem	$5.70 -4.7%	$5.33	$1.00 ▼ $7.19	$214.98M	-0.99	670,884 shs	106,548 shs
HELP Cybin	$13.45 +8.5%	$9.56	$3.76 ▼ $14.35	$1.02B	0.63	1.20 million shs	1.49 million shs
TBPH Theravance Biopharma	$17.06 0.0%	$16.95	$13.08 ▼ $21.03	$885.50M	0.25	562,162 shs	164,156 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-7.66%	-4.97%	+17.89%	+36.35%	+167.58%
ANTX Anthem	+1.53%	+9.12%	+0.84%	+42.38%	+398.33%
HELP Cybin	+1.39%	+6.81%	+6.72%	+220.16%	+1,238,999,900.00%
TBPH Theravance Biopharma	-0.12%	+0.18%	+0.77%	+4.22%	+22.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	96.16% Upside
ANTX Anthem	2.33	Hold	$9.00	49.48% Upside
HELP Cybin	3.00	Buy	$48.60	282.53% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.62% Upside

Current Analyst Ratings Breakdown

Latest ANTX, TBPH, HELP, and ACHV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/27/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$16.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
TBPH Theravance Biopharma	$107.46M	8.25	N/A	N/A	$5.86 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
TBPH Theravance Biopharma	$105.89M	$1.01	16.91	21.08	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest ANTX, TBPH, HELP, and ACHV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
ANTX Anthem	N/A	14.32	14.32
HELP Cybin	N/A	10.97	10.97
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
ANTX Anthem	90.47%
HELP Cybin	17.94%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
ANTX Anthem	22.61%
HELP Cybin	15.00%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
HELP Cybin	50	75.61 million	64.27 million	N/A
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable

ANTX, TBPH, HELP, and ACHV Headlines

Recent News About These Companies

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

3 hours ago | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to "Hold"

September 9 at 7:05 AM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

September 9 at 3:59 AM | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Brokerages

September 2, 2026 | americanbankingnews.com

Theravance Biopharma, Inc. $TBPH is Newtyn Management LLC's 2nd Largest Position

August 31, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Theravance Biopharma, Inc. $TBPH

August 31, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

August 28, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by Analysts

August 28, 2026 | marketbeat.com

Theravance Biopharma Inc

August 20, 2026 | money.usnews.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

August 15, 2026 | businesswire.com

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

August 15, 2026 | marketbeat.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH

August 11, 2026 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

August 10, 2026 | marketbeat.com

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | prnewswire.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | financialpost.comF

Theravance Biopharma Stock Dividends | NASDAQ:TBPH | Benzinga

July 13, 2026 | benzinga.com

Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in Stock

July 2, 2026 | insidertrades.com

Theravance Stock Down 3% After Zymeworks Announces Buyout

June 30, 2026 | zacks.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

June 29, 2026 | prnewswire.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

June 29, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANTX, TBPH, HELP, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$7.58 -0.26 (-3.27%)

As of 03:52 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Anthem NASDAQ:ANTX

$5.70 -0.28 (-4.67%)

As of 03:52 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Cybin NASDAQ:HELP

$13.44 +1.06 (+8.51%)

As of 03:52 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Theravance Biopharma NASDAQ:TBPH

$17.06 -0.01 (-0.03%)

As of 03:52 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, TBPH, HELP, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, TBPH, HELP, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, TBPH, HELP, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, TBPH, HELP, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Anthem NASDAQ:ANTX

Cybin NASDAQ:HELP

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, TBPH, HELP, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, TBPH, HELP, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, TBPH, HELP, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, TBPH, HELP, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Anthem NASDAQ:ANTX

Cybin NASDAQ:HELP

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools